Advertisement

Index by Author

March 1992; 41 (3)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. al-Daccak, R

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  2. Alper, C A

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  3. Aoki, M

    • Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes March 1992 41:334-338; doi:10.2337/diabetes.41.3.334

  4. Appel, M C

    • Multiple TCR V beta usage by infiltrates of young NOD mouse islets of Langerhans. A polymerase chain reaction analysis. Diabetes March 1992 41:308-312; doi:10.2337/diabetes.41.3.308

  5. Awdeh, Z

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

B

  1. Bao, W

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

  2. Beck, F

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

  3. Berenson, G S

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

  4. Björntorp, P

    • Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats. Diabetes March 1992 41:294-298; doi:10.2337/diabetes.41.3.294

  5. Blackman, J D

    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  6. Blantz, R C

    • Renal functional reserve in the early stage of experimental diabetes. Diabetes March 1992 41:267-273; doi:10.2337/diabetes.41.3.267

  7. Bluestone, J A

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  8. Bonner-Weir, S

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  9. Burke, V

    • Differential effect of aspirin on platelet aggregation in IDDM. Diabetes March 1992 41:261-266; doi:10.2337/diabetes.41.3.261

C

  1. Cryer, P E

    • Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes March 1992 41:255-260; doi:10.2337/diabetes.41.3.255

D

  1. Degos, L

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  2. De Nicola, L

    • Renal functional reserve in the early stage of experimental diabetes. Diabetes March 1992 41:267-273; doi:10.2337/diabetes.41.3.267

  3. Deschamps, I

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  4. Douglas, A J

    • Differential effect of aspirin on platelet aggregation in IDDM. Diabetes March 1992 41:261-266; doi:10.2337/diabetes.41.3.261

E

  1. Eisenbarth, G S

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  2. Eriksson, J G

    • Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes March 1992 41:354-358; doi:10.2337/diabetes.41.3.354

  3. Erlich, H

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  4. Exell, L

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

F

  1. Feingold, K R

    • Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats. Diabetes March 1992 41:325-333; doi:10.2337/diabetes.41.3.325

  2. Fujihara, C K

    • Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes March 1992 41:286-293; doi:10.2337/diabetes.41.3.286

G

  1. Gabbai, F B

    • Renal functional reserve in the early stage of experimental diabetes. Diabetes March 1992 41:267-273; doi:10.2337/diabetes.41.3.267

  2. Garvey, W T

    • Glucose and insulin chronically regulate insulin action via different mechanisms in BC3H1 myocytes. Effects on glucose transporter gene expression. Diabetes March 1992 41:274-285; doi:10.2337/diabetes.41.3.274

  3. Gianani, R

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  4. Goto, Y

    • Cell-specific carbohydrate metabolism regulates S14 gene transcription. Diabetes March 1992 41:339-346; doi:10.2337/diabetes.41.3.339

  5. Gress, R E

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  6. Groop, L C

    • Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes March 1992 41:354-358; doi:10.2337/diabetes.41.3.354

H

  1. Herold, K C

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  2. Hilton, C

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

  3. Hirsch, R

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  4. Hors, J

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  5. Huang, B

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

I

  1. Inoue, H

    • Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes March 1992 41:334-338; doi:10.2337/diabetes.41.3.334

J

  1. Jackson, R A

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

K

  1. Kaku, K

    • Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes March 1992 41:334-338; doi:10.2337/diabetes.41.3.334

  2. Kaneko, T

    • Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes March 1992 41:334-338; doi:10.2337/diabetes.41.3.334

  3. Khalil, I

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  4. Korbutt, G S

    • Cold storage of rat pancreas before purification of islet beta-cells. Diabetes March 1992 41:299-307; doi:10.2337/diabetes.41.3.299

L

  1. Lammiman, M J

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

  2. Lee, E T

    • Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. Diabetes March 1992 41:359-367; doi:10.2337/diabetes.41.3.359

  3. Lee, V S

    • Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. Diabetes March 1992 41:359-367; doi:10.2337/diabetes.41.3.359

  4. Lepage, V

    • Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes March 1992 41:378-384; doi:10.2337/diabetes.41.3.378

  5. Lewis, G F

    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  6. Lönnroth, P

    • Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats. Diabetes March 1992 41:294-298; doi:10.2337/diabetes.41.3.294

  7. Lu, M

    • Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. Diabetes March 1992 41:359-367; doi:10.2337/diabetes.41.3.359

M

  1. Maianu, L

    • Glucose and insulin chronically regulate insulin action via different mechanisms in BC3H1 myocytes. Effects on glucose transporter gene expression. Diabetes March 1992 41:274-285; doi:10.2337/diabetes.41.3.274

  2. Mariash, C N

    • Cell-specific carbohydrate metabolism regulates S14 gene transcription. Diabetes March 1992 41:339-346; doi:10.2337/diabetes.41.3.339

  3. Matsutani, A

    • Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes March 1992 41:334-338; doi:10.2337/diabetes.41.3.334

  4. Mayor, P

    • Glucose and insulin chronically regulate insulin action via different mechanisms in BC3H1 myocytes. Effects on glucose transporter gene expression. Diabetes March 1992 41:274-285; doi:10.2337/diabetes.41.3.274

  5. McCulloch, R K

    • Differential effect of aspirin on platelet aggregation in IDDM. Diabetes March 1992 41:261-266; doi:10.2337/diabetes.41.3.261

  6. Melican, D T

    • Multiple TCR V beta usage by infiltrates of young NOD mouse islets of Langerhans. A polymerase chain reaction analysis. Diabetes March 1992 41:308-312; doi:10.2337/diabetes.41.3.308

  7. Mestrez, F

    • Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes March 1992 41:368-377; doi:10.2337/diabetes.41.3.368

  8. Montag, A G

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  9. Mori, T A

    • Differential effect of aspirin on platelet aggregation in IDDM. Diabetes March 1992 41:261-266; doi:10.2337/diabetes.41.3.261

N

  1. Nastasi, K

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

O

  1. O'Neil, J J

    • Multiple TCR V beta usage by infiltrates of young NOD mouse islets of Langerhans. A polymerase chain reaction analysis. Diabetes March 1992 41:308-312; doi:10.2337/diabetes.41.3.308

P

  1. Padilha, R M

    • Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes March 1992 41:286-293; doi:10.2337/diabetes.41.3.286

  2. Pan, X M

    • Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats. Diabetes March 1992 41:325-333; doi:10.2337/diabetes.41.3.325

  3. Parihar, A

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

  4. Pipeleers, D G

    • Cold storage of rat pancreas before purification of islet beta-cells. Diabetes March 1992 41:299-307; doi:10.2337/diabetes.41.3.299

  5. Polonsky, K S

    • Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes March 1992 41:368-377; doi:10.2337/diabetes.41.3.368
    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  6. Pratten, M K

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

  7. Pugliese, A

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

R

  1. Rapp, J H

    • Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats. Diabetes March 1992 41:325-333; doi:10.2337/diabetes.41.3.325

  2. Russell, D

    • Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. Diabetes March 1992 41:359-367; doi:10.2337/diabetes.41.3.359

S

  1. Shiffrin, A J

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  2. Smith, U

    • Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats. Diabetes March 1992 41:294-298; doi:10.2337/diabetes.41.3.294

  3. Soeldner, J S

    • Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes March 1992 41:347-353; doi:10.2337/diabetes.41.3.347

  4. Spire, J P

    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  5. Srinivasan, S R

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

  6. Staprans, I

    • Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats. Diabetes March 1992 41:325-333; doi:10.2337/diabetes.41.3.325

  7. Sturis, J

    • Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes March 1992 41:368-377; doi:10.2337/diabetes.41.3.368
    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  8. Svec, F

    • Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes March 1992 41:313-317; doi:10.2337/diabetes.41.3.313

  9. Svedberg, J

    • Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats. Diabetes March 1992 41:294-298; doi:10.2337/diabetes.41.3.294

T

  1. Towle, V L

    • Hypoglycemic thresholds for cognitive dysfunction in IDDM. Diabetes March 1992 41:392-399; doi:10.2337/diabetes.41.3.392

  2. Town, E

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

  3. Travers, J P

    • Insulin and insulinlike growth factors in embryonic development. Effects of a biologically inert insulin (guinea pig) on rat embryonic growth and development in vitro. Diabetes March 1992 41:318-324; doi:10.2337/diabetes.41.3.318

V

  1. Van Cauter, E

    • Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes March 1992 41:368-377; doi:10.2337/diabetes.41.3.368

  2. Vandongen, R

    • Differential effect of aspirin on platelet aggregation in IDDM. Diabetes March 1992 41:261-266; doi:10.2337/diabetes.41.3.261

W

  1. Waters, S H

    • Multiple TCR V beta usage by infiltrates of young NOD mouse islets of Langerhans. A polymerase chain reaction analysis. Diabetes March 1992 41:308-312; doi:10.2337/diabetes.41.3.308

  2. Widén, E I

    • Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes March 1992 41:354-358; doi:10.2337/diabetes.41.3.354

  3. Wiegner, A

    • Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes March 1992 41:385-391; doi:10.2337/diabetes.41.3.385

Z

  1. Zatz, R

    • Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes March 1992 41:286-293; doi:10.2337/diabetes.41.3.286

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement